| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203306LU2313OA |
| P698 | PubMed publication ID | 16830883 |
| P50 | author | Michelle A. Petri | Q67485110 |
| P2093 | author name string | M Haas | |
| L S Magder | |||
| D M Fine | |||
| N Kasitanon | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors | Q29615065 | ||
| Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. | Q33731760 | ||
| The classification of glomerulonephritis in systemic lupus erythematosus revisited | Q34293066 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group | Q41926859 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial | Q44747066 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| P433 | issue | 6 | |
| P921 | main subject | hydroxychloroquine | Q421094 |
| P304 | page(s) | 366-370 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis | |
| P478 | volume | 15 |
| Q37131283 | 2013 update: Hopkins lupus cohort |
| Q41922844 | A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis |
| Q37577571 | A perspective on B-cell-targeting therapy for SLE. |
| Q34184151 | Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort |
| Q41939554 | Antimalarials. A treatment option for every lupus patient!? |
| Q37371383 | Beyond immunosuppression - challenges in the clinical management of lupus nephritis |
| Q88931744 | Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring |
| Q36663933 | Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). |
| Q47218712 | Chronicity index, especially glomerular sclerosis, is the most powerful predictor of renal response following immunosuppressive treatment in patients with lupus nephritis. |
| Q41540102 | Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis |
| Q33422958 | Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus |
| Q38997792 | Dialogue: Early predictors of long-term lupus nephritis outcomes: looking into the future |
| Q37324772 | Drugs in early clinical development for Systemic Lupus Erythematosus |
| Q31107094 | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) |
| Q50222848 | Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort |
| Q41922310 | Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study |
| Q92026856 | Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues |
| Q90157934 | Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy |
| Q36240425 | Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence |
| Q51083193 | Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. |
| Q38029146 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects |
| Q60018821 | Hydroxychloroquine in systemic lupus erythematosus |
| Q34162739 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus |
| Q26782822 | Hydroxychloroquine-related retinal toxicity |
| Q46643929 | Hydroxychloroquine: the cornerstone of lupus therapy |
| Q47396929 | Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? |
| Q40891083 | Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome |
| Q38883883 | Immunomodulators in SLE: Clinical evidence and immunologic actions |
| Q54365434 | Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. |
| Q36820979 | Lupus activity in pregnancy |
| Q38362113 | Lupus in Latin-American patients: lessons from the GLADEL cohort. |
| Q38446941 | Lupus nephritis management guidelines compared |
| Q92625510 | Management strategies and future directions for systemic lupus erythematosus in adults |
| Q44913899 | Managing lupus nephritis in pregnant women: comment on the article by Hahn et al. |
| Q30655475 | Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort |
| Q46076332 | Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study |
| Q38816742 | New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity |
| Q47100353 | Predictors of incident proteinuria among patients with SLE. |
| Q41929732 | Predictors of survival in Chinese patients with lupus nephritis |
| Q87478283 | Presentation and outcome of paediatric membranous non-proliferative lupus nephritis |
| Q41941085 | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival |
| Q33455990 | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort |
| Q38831841 | Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis |
| Q33885872 | Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. |
| Q31129756 | Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). |
| Q44108515 | Statement on the use of mycophenolate mofetil for systemic lupus erythematosus |
| Q39053129 | Systemic lupus erythematosus diagnosis and management |
| Q93193261 | Systemic lupus erythematosus: Diagnosis and clinical management |
| Q38709337 | TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells |
| Q35692998 | The Diagnosis and Treatment of Systemic Lupus Erythematosus |
| Q37947108 | The role of antimalarial agents in the treatment of SLE and lupus nephritis |
| Q38897055 | Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q27005906 | Unmet medical needs in systemic lupus erythematosus |
| Q38920435 | Why targeted therapies are necessary for systemic lupus erythematosus |
Search more.